Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Phase 2Active, not recruiting
- Start
- May 2019
- Primary completion
- Jul 2026
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 13
01
Overview
A Phase 2 trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD). Started May 2019; status: active, not recruiting.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03253263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253263.